Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M31.0Revenue $M0.1Net Margin (%)-8,021.4Altman Z-Score14.2
Enterprise Value $M31.1EPS $-0.6Operating Margin %-10,886.5Piotroski F-Score4
P/E(ttm)--Beneish M-Score-3.5Pre-tax Margin (%)-8,209.0Higher ROA y-yN
Price/Book1.010-y EBITDA Growth Rate %-20.0Quick Ratio25.1Cash flow > EarningsY
Price/Sales2765-y EBITDA Growth Rate %-31.6Current Ratio25.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-28.1Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-30.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M16.9ROIC % (ttm)-964.1Gross Margin Increase y-yN

Gurus Latest Trades with NVGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
NVGNRonald Muhlenkamp 2013-03-31 Sold Out -0.03%$1.84 - $9.05
$ 1.83-52%Sold Out0
NVGNRonald Muhlenkamp 2012-12-31 Reduce-0.01%$1.5 - $10.24
$ 1.83-63%Reduce -49.15%18,184
NVGNRonald Muhlenkamp 2012-06-30 Buy 0.02%$1.95 - $2.5
$ 1.83-19%New holding35,757
NVGNRonald Muhlenkamp 2011-12-31 Reduce-0.01%$0.66 - $1.19
$ 1.83115%Reduce -32.42%35,758
NVGNRonald Muhlenkamp 2011-09-30 Add$0.92 - $2.14
$ 1.8338%Add 4.70%52,915
NVGNRonald Muhlenkamp 2011-06-30 Reduce$1.32 - $2.95
$ 1.83-10%Reduce -1.45%50,542
NVGNRonald Muhlenkamp 2011-03-31 Add$0.84 - $3.57
$ 1.8324%Add 1.88%51,287
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVGN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

NVGN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about NVGN:

    News about NVGN:

    Articles On GuruFocus.com
    Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and NeoPhotonic Mar 04 2015 

    More From Other Websites
    Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed Feb 05 2016
    Letter to Shareholders from CEO James Garner Jan 31 2016
    Novogen appoints new CEO Dec 09 2015
    Novogen Appoints Dr James Garner as Chief Executive Officer Dec 09 2015
    NOVOGEN LTD Financials Dec 08 2015
    Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial Nov 23 2015
    Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia Nov 11 2015
    Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina Nov 10 2015
    Novogen Applies for Long-Term Options Listing on ASX Sep 30 2015
    Novogen Applies for Long-term Options Listing Sep 29 2015
    Novogen (NVGN) Conducts Scientific Review of R&D Program Aug 31 2015
    Novogen Announces The Outcome Of A Comprehensive Science Review Aug 30 2015
    Novogen to review pre-clinical programs Jul 30 2015
    Newly Appointed Acting CEO Outlines Immediate Plans for Novogen Jul 29 2015
    Novogen to review its pre-clinical trials Jul 29 2015
    Former CEO: Novogen in sound position Jul 21 2015
    Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board Jul 21 2015
    Novogen shares tumble Jul 21 2015
    Novogen chief executive resigns Jul 21 2015
    Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma Jul 16 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)